Opinion
Video
Author(s):
Bladder cancer experts discuss quality of life and progression considerations and their impact on treatment decisions for patients with BCG-unresponsive NMIBC.
Nadofaragene firadenovec elicits high CR rate in phase 3 trial in Japan
Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care
U.S. News & World Report Names Michigan Institute of Urology’s Town Center ASC Among 2025 Best Ambulatory Surgery Centers
Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease
Exploring new avenues in non–muscle invasive bladder cancer treatment
FDA approval sought for Anktiva in papillary NMIBC